Risk adjusted net present value: What is the current valuation of Bavarian Nordic’s PXVX-0317?

PXVX-0317 is a subunit vaccine commercialized by Bavarian Nordic, with a leading Phase III program in Chikungunya Fever.

Vonoprazan fumarate by Phathom Pharmaceuticals for Reflux Esophagitis (Gastroesophageal Reflux Disease): Likelihood of Approval – Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

November 4, 2023

Residents, Blink Twice for Help; Strangest GI Bugs; Playlists for the OR

The following contains links to social media websites including X, TikTok, Instagram, Facebook, and LinkedIn. After sixth-year neurosurgery resident John Andrews, MD, went viral on

November 17, 2023

JAX offers a fully validated, clinical whole genome sequencing test

Until quite recently, it was extremely difficult to detect the variants underlying many genetic disorders. In the absence of a defined cause, clinicians have little

September 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.